1. OMS: Organización Mundial de la Salud. Informe sobre la situación mundial de las enfermedades no transmisibles 2010. Disponible en: http://www.who.int/nmh/publications/ncd_report2010/es/. Consultado 2 Oct 2017.
2. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease;Schmidt;Cochrane Database Syst Rev.,2017
3. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med.,2017
4. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of alirocumab on the occurrence of cardiovascular events in patients who have recently experienced an acute coronary syndrome. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01663402. Consultado 29 Ago 2017.
5. National Institute for Health and Care Excellence. Putting NICE guidance into practice. Resource impact report: Alirocumab (TA393) and evolocumab (TA394) for treating primary hypercholesterolaemia and mixed dyslipidaemia. National Institute for Health and Care Excellence. 2016. Disponible en: https://www.nice.org.uk/guidance/ta394/resources/resource-impact-report-pdf-2543362381. Consultado 2 Ago 2017.